Evidence map›Paper›PMID 38523431›Full record

ArticleGenesis (New York, N.Y. : 2000)2024

An oocyte-specific Cas9-expressing mouse for germline CRISPR/Cas9-mediated genome editing.

Denise G Lanza, Jianqiang Mao, Isabel Lorenzo, Lan Liao, John R Seavitt, M Cecilia Ljungberg, Elizabeth M Simpson, Francesco J DeMayo, Jason D Heaney

Open access · greenAbstract read
In one paragraph

Article in Genesis (New York, N.Y. : 2000), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Phosphorylation of RYR1 at SerScience signaling · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Denise G LanzaDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0001-8750-6933
Jianqiang MaoDepartment of Molecular & Cellular Biology, Baylor College of Medicine, Houston, Texas, USA.
Isabel LorenzoDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
Lan LiaoDepartment of Molecular & Cellular Biology, Baylor College of Medicine, Houston, Texas, USA.
John R SeavittDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
M Cecilia LjungbergDepartment of Pediatrics - Neurology, Baylor College of Medicine, Houston, Texas, USA.
Elizabeth M SimpsonCentre for Molecular Medicine and Therapeutics at BC Children's Hospital, Department of Medical Genetics, The University of British Columbia, Vancouver, British Columbia, Canada.
Francesco J DeMayoReproductive and Developmental Biology Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA.ORCID 0000-0002-9480-7336
Jason D HeaneyDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0001-8475-8828
Baylor College of Medicine · USNational Institute of Environmental Health Sciences · USUniversity of British Columbia · CA

Funding

Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Suzanne AW Fuqua · 2007 to 2026
$73.9M
UM1HG006348: Cas9 Genome Integrity Supplemental ProposalUM1HG006348 · NHGRI · BAYLOR COLLEGE OF MEDICINE · PI Jason D. Heaney, Chih-Wei Logan Hsu · 2016 to 2026
$47.5M
Environmental Signaling in Reproduction and PregnancyZIAES103311 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI DEMAYO, FRANCESCO · 2016 to 2025
$30.5M
Resource and Service SectionU54OD030165 · OD · BAYLOR COLLEGE OF MEDICINE · PI Lindsay C Burrage · 2020 to 2026
$16.6M
Tecan EVO GenePaint robotS10OD016167 · OD · BAYLOR COLLEGE OF MEDICINE · PI LJUNGBERG, CECILIA · 2013 to 2013
$215k
NCI NIH HHS P30 CA125123NHGRI NIH HHS UM1 HG006348NIH HHS P30CA12512NIH HHS S10 OD016167NIH HHS U54 OD030165NIH HHS UM1 HG006348
6 · The paper itself

Abstract

Cas9 transgenes can be employed for genome editing in mouse zygotes. However, using transgenic instead of exogenous Cas9 to produce gene-edited animals creates unique issues including ill-defined transgene integration sites, the potential for prolonged Cas9 expression in transgenic embryos, and increased genotyping burden. To overcome these issues, we generated mice harboring an oocyte-specific, Gdf9 promoter driven, Cas9 transgene (Gdf9-Cas9) targeted as a single copy into the Hprt1 locus. The X-linked Hprt1 locus was selected because it is a defined integration site that does not influence transgene expression, and breeding of transgenic males generates obligate transgenic females to serve as embryo donors. Using microinjections and electroporation to introduce sgRNAs into zygotes derived from transgenic dams, we demonstrate that Gdf9-Cas9 mediates genome editing as efficiently as exogenous Cas9 at several loci. We show that genome editing efficiency is independent of transgene inheritance, verifying that maternally derived Cas9 facilitates genome editing. We also show that paternal inheritance of Gdf9-Cas9 does not mediate genome editing, confirming that Gdf9-Cas9 is not expressed in embryos. Finally, we demonstrate that off-target mutagenesis is equally rare when using transgenic or exogenous Cas9. Together, these results show that the Gdf9-Cas9 transgene is a viable alternative to exogenous Cas9.

Indexed as

CRISPR-Cas SystemsGene EditingAnimalsAnimals, Genetically ModifiedFemaleMaleMiceMutationOocytesRNA, Guide, CRISPR-Cas SystemsZygoteRNA, Guide, CRISPR-Cas SystemsCRISPRgenome editinggermline mutationsSpCas9

Identifiers

PMID38523431
PMCPMC10987075
OpenAlexW4393152183

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.